Sales 2024 * | 632M 862M | Sales 2025 * | 716M 976M | Capitalization | 3.13B 4.27B |
---|---|---|---|---|---|
Net income 2024 * | 109M 149M | Net income 2025 * | 155M 211M | EV / Sales 2024 * | 4.03 x |
Net cash position 2024 * | 584M 797M | Net cash position 2025 * | 706M 963M | EV / Sales 2025 * | 3.39 x |
P/E ratio 2024 * |
32.5
x | P/E ratio 2025 * |
22.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.18% |
Latest transcript on Corcept Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Atabak Mokari
DFI | Director of Finance/CFO | 47 | 21-02-28 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 46 | 12-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-03-11 |
George Baker
BRD | Director/Board Member | 81 | 98-12-31 |
1st Jan change | Capi. | |
---|---|---|
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |